We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




CRISPR Genome-Editing System Avoids DNA Strand Breaks

By LabMedica International staff writers
Posted on 29 Aug 2018
A variation of the CRISPR/Cas9 genome-editing tool enables more precise manipulation of target genes by not breaking double stranded DNA and instead modifying a single point in the targeted DNA sequence.

CRISPR gene editing has revolutionized biomedicine and biotechnology by providing a simple means to engineer genes through targeted double-strand breaks in the genomic DNA of living cells. More...
However, given the random nature of cellular DNA repair mechanisms and the potential for off-target mutations, technologies capable of introducing targeted changes with increased precision, such as single-base editors, are preferred.

In this regard, a single-base editing system called CRISPR-SKIP was described by investigators at the University of Illinois (Champaign, USA) in the August 15, 2018, online edition of the journal Genome Biology. This method utilized cytidine deaminase single-base editors to program exon skipping by mutating target DNA bases within splice acceptor sites. Thus, CRISPR-SKIP altered a single base before the beginning of an exon, causing the cell to read it as a non-coding portion.

The modified exon was not included in mature RNA, which prevented the corresponding amino acids from becoming part of the protein product. Proteins that are missing a few amino acids often retain partial or full activity, which may be enough to restore function in some genetic diseases.

"Given the problems with traditional gene editing by breaking the DNA, we have to find ways of optimizing tools to accomplish gene modification. This is a good one because we can regulate a gene without breaking genomic DNA," said senior author Dr. Pablo Perez-Pinera, professor of bioengineering at the University of Illinois.

"In Duchenne's muscular dystrophy, for example, just correcting 5% to 10% of the cells is enough to achieve a therapeutic benefit. With CRISPR-SKIP, we have seen modification rates of more than 20% to 30% in many of the cell lines we have studied," said Dr. Perez-Pinera.

Related Links:
University of Illinois


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.